Recent Reports

ICER’s Draft Evidence Report on treatments for cystic fibrosis, open to public comment until March 18th. For more information on submitting a public comment, please visit ourstakeholder engagement page. 

View More on this Topic



ICER’s Draft Evidence Report on treatments for sickle cell disease, open to public comment until February 20, 2020. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic

Evidence report on acute migraine treatmentsThis report served as the basis for discussion during a public meeting on January 23, 2020.

View More on this Topic

ICER’s final report on JAK inhibitors for rheumatoid arthritis, including a summary of the public meeting and key policy recommendations.

View More on this Topic


Materials

New England CEPAC

Supervised Injection Facilities: Open Input

Midwest CEPAC

Bladder Cancer: Open Input

Midwest CEPAC

Digital Apps for OUD: Open Input

ICER

2020 Value Assessment Framework: Response to Comments

CTAF

RA Update: Final Policy Recommendations

ICER

2020 Value Assessment Framework: Final Webcast to Explain Updates

New England CEPAC

Hemophilia A Update: Open Input Period

New England CEPAC

Hemophilia A Update: Stakeholder List

New England CEPAC

Hemophilia A Update: Draft Scoping Document

New England CEPAC

Diabetes: Final Policy Recommendations

New England CEPAC

Beta Thalassemia: Revised Scoping Document

New England CEPAC

Beta Thalassemia: Stakeholder List